Investigational drug · Phase 2
SHR-1826
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Lung Cancer (NSCLC), Non-Small Cell Lung Cancer, Resectable Non-small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
9
Any phase or sponsor naming "SHR-1826"
First trial start
2025
Feb 18, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR-1826", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer (NSCLC)
- Non-Small Cell Lung Cancer
- Resectable Non-small Cell Lung Cancer
- Advanced Solid Tumors
- Advanced Malignant Tumour
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR-1826" as an intervention, largest first.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT06703177 · 876 participants (planned) · Start Feb 18, 2025 · Primary completion Jan 1, 2026
Drug: SHR-1826; SHR-4642 and 7 more · For: Advanced Solid Tumors
Sites: Guangzhou, China
- A Phase Ib Study of HS-10504 Combined Therapy in NSCLCNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07414953 · 400 participants (planned) · Start Mar 30, 2026 · Primary completion Apr 30, 2027
Drug: HS-10504; SHR-A2009 and 4 more · For: Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT06754930 · 400 participants (planned) · Start Feb 18, 2025 · Primary completion Dec 2027
Drug: SHR-1826; SHR-1316 and 5 more · For: Non-small Cell Lung Cancer (NSCLC)
Sites: Shanghai, China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT06844474 · 300 participants (planned) · Start Mar 7, 2025 · Primary completion Dec 2026
Drug: SHR-1826;Adebrelimab;SHR-8068;Bevacizumab · For: NSCLC
Sites: Beijing, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06915142 · 300 participants (planned) · Start Apr 28, 2025 · Primary completion Dec 2026
Drug: HRS-7058 + SHR-1316; HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy and 11 more · For: Advanced Malignant Tumour
Sites: Beijing, China; Tianjin, China
- An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid TumorsRecruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT06094556 · 240 participants (planned) · Start Dec 25, 2023 · Primary completion Jun 30, 2027
Drug: SHR-1826 · For: Advanced Solid Tumors
Sites: Guangzhou, China
- The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung CancerNot yet recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07704645 · 180 participants (planned) · Start Aug 2026 · Primary completion Jun 2028
Drug: Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection; Adebrelimab Injection combined with HRS-7058 Capsule · For: Resectable Non-small Cell Lung Cancer
Sites: Shanghai, China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07489716 · 90 participants (planned) · Start Apr 29, 2026 · Primary completion Aug 2028
Drug: SHR-1826 · For: Non-Small Cell Lung Cancer
Sites: Jinan, China
- A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular CancerNot yet recruiting
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT06935175 · 53 participants (planned) · Start May 1, 2025 · Primary completion May 31, 2027
Drug: SHR-1826; SHR-1826 and immunotherapy combination therapy · For: Hepatocellular Cancer
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Non-small Cell Lung Cancer (NSCLC)
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- Rina-SPRO1184, GEN1184Phase 39 trials
Genmab · Ovarian Cancer, Platinum-resistant Ovarian Cancer, Endometrial Cancer
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
- AtebimetinibIMM-1-104, Group APhase 34 trials
Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)
- H2 receptor antagonistPhase 34 trials
Merck & Co. · Lung Neoplasm Malignant, Esophageal Squamous Cell Carcinoma, Ovarian Cancer
- H1 receptor antagonistPhase 33 trials
Merck & Co. · Lung Neoplasm Malignant, Ovarian Cancer, Fallopian Tube Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.